Filing Analysis
Predictive Oncology Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. As of September 30, 2024, the company's stockholders' equity was $1.97 million, falling below the required $2.5 million threshold.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirement.
- Failure to meet alternative compliance standards (market value and net income).
- Potential delisting risk if a compliance plan is not accepted or executed within the extension period.
📋 Key Facts
- Received Nasdaq notice on November 20, 2024.
- Stockholders' equity as of Sept 30, 2024: $1,966,969 (Requirement: $2.5 million).
- Company failed alternative compliance standards regarding market value ($35M) and net income ($500k).
- Deadline to submit a plan to regain compliance is January 6, 2025.
- If a plan is accepted, the company may receive an extension of up to 180 days to evidence compliance.
Predictive Oncology Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing was made on November 13, 2024.
- The report covers the quarter ended September 30, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Predictive Oncology Inc. received a deficiency notice from Nasdaq because its common stock closed below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Stock price has been consistently below $1.00 (penny stock territory)
📋 Key Facts
- The company is currently non-compliant with Nasdaq Marketplace Rule 5550(a)(2).
- The deficiency was triggered by the stock closing below $1.00 for 30 consecutive business days.
- The company has a compliance period of 180 days, expiring on March 18, 2025.
- Compliance can be regained if the bid price closes at or above $1.00 for 10 consecutive business days before the deadline.
- To qualify for an additional compliance period, the company may need to effect a reverse stock split.
Predictive Oncology Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2024.
📋 Key Facts
- The filing relates to the announcement of financial results for the quarter ending June 30, 2024.
- The report was filed on August 14, 2024.
- The company is listed on the Nasdaq Capital Market under the symbol POAI (noted in text as AGPU/POAI transition).
- Interim CFO Josh Blacher signed the filing.
Predictive Oncology Inc. entered into agreements to facilitate the immediate exercise of existing warrants at a significantly reduced price, raising approximately $1.26 million in gross proceeds. In exchange for this cash infusion, the company issued new Series A and Series B warrants to holders with low exercise prices ($1.07) and additional warrants to the placement agent.
🚩 Red Flags
- Extreme warrant dilution: The reduction of exercise price from $14.00 to $1.32 represents a massive downward adjustment, signaling significant distress or an attempt to prevent expiration/default.
- Death spiral characteristics: The issuance of new warrants (Series A and B) at very low strike prices ($1.07) creates substantial future dilution for existing shareholders.
- Heavy reliance on dilutive financing: The company is using 'warrant inducement' to secure immediate, albeit small, amounts of cash ($1.26M).
- High transaction costs: Placement agent fees and warrant compensation represent a significant portion of the capital raised.
📋 Key Facts
- Existing warrants (issued Feb/May 2021 & June 2021) were exercised at a reduced price of $1.32 per share, down from an original exercise price of $14.00.
- Gross proceeds from the warrant exercise totaled approximately $1.26 million.
- Company issued new Series A Warrants (5-year term) and Series B Warrants (18-month term) with an exercise price of $1.07 per share to existing holders.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving cash fees totaling 8% plus expenses and compensation warrants for 67,068 shares at $1.65/share.
- Proceeds are intended for working capital and general corporate purposes.
Predictive Oncology Inc. filed an 8-K to announce a press release issued on May 28, 2024. The filing does not contain specific financial data or material event details in the body text, referring instead to Exhibit 99.1.
📋 Key Facts
- Report date: May 28, 2024
- Filing date: May 30, 2024
- The company issued a press release on May 28, 2024 (Exhibit 99.1)
- Interim CFO Josh Blacher signed the report
Predictive Oncology Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: May 15, 2024.
- Period covered: Quarter ended March 31, 2024.
- The company issued a press release as Exhibit 99.1 to accompany the results.
Predictive Oncology Inc. entered into an 'at the market' (ATM) sales agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $3,696,000 in common stock.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can signal liquidity needs.
📋 Key Facts
- Entered into ATM Sales Agreement on May 3, 2024.
- Sales agent: H.C. Wainwright & Co., LLC.
- Maximum offering amount: $3,696,000.
- Wainwright compensation: 3.0% of the gross sales price.
- Issuance is subject to the effectiveness of a Form S-3 registration statement filed on May 3, 2024.
Predictive Oncology Inc. has dismissed its independent auditor, BDO USA, P.C., and engaged KPMG LLP for the fiscal year ending December 31, 2024. The dismissal follows a period where the previous auditor issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language: The 2023 BDO Report contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting (accounting resources and IT general controls).
- History of reverse stock split adjustments noted in recent audits.
📋 Key Facts
- Effective April 3, 2024, BDO USA, P.C. was dismissed as the independent auditor.
- KPMG LLP has been engaged for the fiscal year ending December 31, 2024 (pending standard client evaluation).
- The previous auditor's report for the year ended Dec 31, 2023, contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- BDO audited adjustments to 2022 financial statements related to a reverse stock split and changes in reportable segments.
- Material weaknesses were identified in internal control over financial reporting regarding inadequate accounting resources for complex transactions and IT general controls (user access/segregation of duties).
Predictive Oncology Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of their annual earnings press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an earnings press release as Exhibit 99.1
- Interim CFO Josh Blacher signed the report
This is an 8-K/A amendment regarding the results of a shareholder advisory vote. The company's stockholders voted to maintain annual 'Say-on-Pay' votes, and the Board has committed to conducting these votes every year for the foreseeable future.
📋 Key Facts
- The filing is an amendment (8-K/A) to an original 8-K filed on December 2, 2022.
- Stockholders voted in favor of conducting 'Say-on-Pay' votes every year rather than every two or three years.
- The Board of Directors will re-evaluate the frequency determination after the next Say-on-Frequency Proposal, which must occur no later than the 2028 annual meeting.
Predictive Oncology Inc. announced the departure of its Chief Business Officer, Pamela Bush, Ph.D., MBA, effective February 15, 2024. The company is currently searching for a replacement as part of its corporate development strategy.
🚩 Red Flags
- Departure of a key executive (Chief Business Officer) in a micro-cap biotech company can sometimes signal internal strategic shifts or friction, though not explicitly stated here.
📋 Key Facts
- Pamela Bush, Ph.D., MBA, will leave her role as Chief Business Officer on February 15, 2024.
- The departure was by mutual agreement between the Company and Dr. Bush.
- The company has initiated a search to fill the Chief Business Officer position.
Predictive Oncology Inc. reported the results of its Annual Meeting of Stockholders held on December 28, 2023. The meeting included the election of three Class II directors and the ratification of BDO USA, P.C. as independent auditors.
🚩 Red Flags
- Shareholders rejected the 2023 Equity Incentive Plan, which may indicate dissatisfaction with dilution or compensation structures.
- High number of Broker Non-Votes (1,023,553) across all items suggests significant institutional or non-participating shareholder presence.
📋 Key Facts
- Annual Meeting held on December 28, 2023.
- Three Class II directors elected: Gregory St. Clair, Sr., Nancy Chung-Welch, Ph.D., and Matthew J. Hawryluk, Ph.D.
- BDO USA, P.C. was ratified as the independent auditor for 2023 with 1,628,338 votes in favor.
- The proposal to approve the 2023 Equity Incentive Plan failed to pass (432,129 'For' vs 435,447 'Against').
- A non-binding advisory resolution on executive compensation was approved.